FCGR3A and FCGR3B mRNA level in peripheral blood of patients with benign prostate hyperplasia

Arioua K., Novikov D.V., Korovin O.A., Alyasova A.V., Novikov V.V.

National Research Lobachevsky State University of Nizhny Novgorod, Russia
Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology named after Academician I.N. Blokhina of Rospotrebnadzor, Russia
City Hospital № 33, Nizhny Novgorod, Russia
Privolzhsky Research Medical University, Nizhny Novgorod, Russia

The mechanisms of immunopathological disorders accompanying the development of prostatic hyperplasia are not well understood. Using real-time RT-PCR, we assessed the pattern of changes in the levels of FCGR3A mRNA encoding CD16A and FCGR3B mRNA encoding CD16B in the peripheral blood of patients with benign prostatic hyperplasia. It was found that the levels of FCGR3A mRNA and FCGR3B mRNA in the blood of patients with prostate adenoma did not significantly differ from the norm, did not depend on the level of prostate-specific antigen, the coefficient of stiffness and the location of tumor nodes. However, the level of mRNA FCGR3A increased many times with an increase in the age of patients and decreased with an increase in the content of testosterone in the serum of patients, and the level of mRNA FCGR3B decreased with an increase in the volume of a benign tumor and the size of the adenomatous node in the gland. Identified changes in expression of genes encoding CD16A and CD16B molecules may be associated with the development of benign prostatic hyperplasia and its transformation into prostate cancer.